Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CTSC | P53634 | 4/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20811542 | 0.95 | KCNH2 (0.51) | MC4RKCNH2CTSCP2RX7HTR2C | |
| SCHEMBL30524906 | 0.95 | KCNH2 (0.51) | MC4RKCNH2CTSCP2RX7HTR2C | |
| SCHEMBL17346737 | 0.83 | MTOR (0.44) | KCNH2CTSC | |
| SCHEMBL30524872 | 0.83 | KCNH2 (0.51) | MC4RKCNH2P2RX7HTR2CMAOA | |
| Trifluoroacetic Acid SCHEMBL22206743 | 0.83 | HTR2C (0.57) | MC4RKCNH2P2RX7HTR2CEPHX2 | |
| SCHEMBL15843967 | 0.83 | MTOR (0.44) | KCNH2CTSC | |
| Trifluoroacetic Acid SCHEMBL22206741 | 0.83 | HTR2C (0.57) | MC4RKCNH2P2RX7HTR2CEPHX2 | |
| SCHEMBL18556183 | 0.82 | CTSC (0.59) | MC4RCTSCHTR2C | |
| SCHEMBL7067405 | 0.82 | CTSC (0.59) | MC4RCTSCHTR2C | |
| SCHEMBL5227415 | 0.82 | CTSC (0.47) | MC4RCTSCHTR2CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | MC4R 3564/4885KCNH2 111/4885CTSC 3422/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | MC4R 3564/4885KCNH2 111/4885CTSC 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.